Reimbursement of Biosimilar and Biosimilar-similar ESAs
This article was originally published in RPM Report
Executive Summary
Affymax received FDA approval for the first new ESA in years. Now the company is trying to secure favorable reimbursement for its product, Omontys. The case raises the question of how CMS will treat biosimilar ESAs.